Skip to content
Helping patients reclaim a life of possibility
Clear
Search
Menu
About us
Contact us
Myeloma and AL Amyloidosis
About Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month 2025
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
European Young Myeloma Patients Group
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
European Myeloma Day
News
Myeloma and AL Amyloidosis
About Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month 2025
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
European Young Myeloma Patients Group
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
European Myeloma Day
News
Day: March 1, 2023
Job offer – Medical and Scientific officer
MPE
March 1, 2023
T2EVOLVE and QUALITOP launch European patient survey on CAR-T treatment
Myeloma
March 1, 2023
Go to Top
About MPE
Our members
Our board and staff
Medical Advisory Commitee
Our Strategic Goals
Our funding
Get involved in MPE activities
Become a member
Contact us
Myeloma and AL Amyloidosis
About Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month 2025
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
News
European Myeloma Day
Clear
Search
PopUp
I am a
*
Patient
Patient advocate
Caregiver
Doctor
Name
This field is for validation purposes and should be left unchanged.
